FBIO Earnings
Fortress Biotech Inc
$
1.930
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Fortress Biotech Inc(FBIO) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Fortress Biotech Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2024Q1 | 2024-05-15 | - | -2.03 | -1.03 | +49.26 | 14.13M | 13.03M | -7.79 | -1.14 | +12.50 |
| FY2023Q4 | 2024-03-28 | - | - | -0.53 | - | 15.11M | 20.59M | +36.26 | -7.83 | -13.82 |
| FY2023Q3 | 2023-11-14 | - | -3.53 | -0.94 | +73.37 | 15.91M | 34.75M | +118.50 | -1.49 | +108.96 |
| FY2023Q2 | 2023-08-14 | - | -0.26 | -0.24 | +7.69 | 17.47M | 17.39M | -0.45 | +1.89 | -16.98 |
| - | 2023-05-15 | - | -0.19 | -0.21 | -10.53 | - | - | - | -1.39 | -27.78 |
| - | 2023-03-30 | - | -0.22 | -0.30 | -36.36 | - | - | - | -3.90 | -5.19 |
| - | 2022-11-14 | - | -0.27 | -0.25 | +7.41 | - | - | - | +6.17 | - |
| - | 2022-08-11 | - | -0.20 | -0.24 | -20.00 | - | - | - | +6.61 | -3.31 |
| - | 2022-05-12 | - | -0.28 | -0.18 | +35.71 | - | - | - | - | +8.75 |
| - | 2022-03-28 | - | 0.10 | -0.38 | -480.00 | - | - | - | +5.97 | +4.48 |
FBIO Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Fortress Biotech Inc reported performance for FY2024Q1, announced on 2024-05-15. The company achieved an EPS of -1.03, compared to analyst estimates of -2.03 by 49.26% . Revenue for the quarter reached 13.03M compared to expectations of 14.13M by -7.79% .
The stock price reacted with a -1.14% one-day change and a 12.50% five-day change following the earnings release. These movements reflect market reaction in Fortress Biotech Inc growth trajectory and strategic initiatives.
FBIO Earnings Forecast
Looking ahead, Fortress Biotech Inc(FBIO) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 14.53M and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been Revise Downward by -0.67%. For the upcoming , revenue estimates have been adjusted Go Up by 10.92% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Fortress Biotech Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between FBIO's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Downward
-0.67%
In Past 3 Month
Stock Price
Go Up
+10.92%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:73.02M
--
EPS Estimate-Annual FY 2025:0
—
Stock Price1.93
FBIO Revenue and EPS Performance: A Historical Perspective
Fortress Biotech Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2024Q1 (2024-05-15,):
EPS: -1.03 (Actual) vs.-2.03 (Estimate) (49.26%)
Revenue: 13.03M (Actual) vs. 14.13M (Estimate) (-7.79%)
Price Reaction: -1.14%(1-Day), 12.50%(5-Day)
FY2023Q4 (2024-03-28,):
EPS: -0.53 (Actual) vs. (Estimate) (%)
Revenue: 20.59M (Actual) vs. 15.11M (Estimate) (36.26%)
Price Reaction: -7.83%(1-Day), -13.82%(5-Day)
FY2023Q3 (2023-11-14,):
EPS: -0.94 (Actual) vs.-3.53 (Estimate) (73.37%)
Revenue: 34.75M (Actual) vs. 15.91M (Estimate) (118.50%)
Price Reaction: -1.49%(1-Day), 108.96%(5-Day)
Earnings Reaction
The chart below shows how FBIO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, FBIO sees a +3.04% change in stock price 10 days leading up to the earnings, and a -4.96% change 10 days following the report. On the earnings day itself, the stock moves by +0.49%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2024, the stock changed 1.15% on the day following the earnings release and then changed by 5.17% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Fortress Biotech Inc (FBIO) Q4 2024 Earnings Call Summary
Negative
2025-03-26
The earnings call reveals significant challenges: a substantial net loss, decreased revenues, and limited payer coverage for Emrosi. Regulatory risks and supply chain issues further exacerbate concerns. Management's vague responses in the Q&A section and absence of guidance contribute to uncertainty. While there is potential in Emrosi's market, the current financial instability and competitive pressures overshadow optimism, leading to a likely negative stock price movement.
Fortress Biotech Inc (FBIO) Q4 2024 Earnings Call Summary
Negative
2025-03-26
The earnings call highlights several negative aspects: increased net loss, declining revenues, and reduced EBITDA. Regulatory and market competition risks are significant, with only 20% payer coverage for Emrosi. The Q&A reveals management's reluctance to provide clear guidance, which could worry investors. Despite some cost optimizations, the financial outlook remains weak, and the lack of guidance suggests uncertainty. These factors outweigh any positive aspects like potential sales growth, leading to a negative sentiment.
People Also Watch
SSBI
Summit State Bank
11.750
USD
-1.01%
CLST
Catalyst Bancorp Inc
12.550
USD
-0.05%
OPI
Office Properties Income Trust
0.240
USD
+0.42%
MDIA
Mediaco Holding Inc
1.320
USD
-4.35%
BEDU
Bright Scholar Education Holdings Ltd
1.700
USD
0.00%
KSCP
Knightscope Inc
5.950
USD
0.00%
ARKR
Ark Restaurants Corp
7.300
USD
+4.58%
NVNI
Nvni Group Ltd
0.620
USD
-9.88%
FAQ
What were the key highlights of FBIO’s latest earnings report for FY2024Q1?
FBIO reported its FY2024Q1 earnings on 2024-05-15, showcasing a revenue of 13.03M against an estimate of 14.13M, resulting in a -7.79% surprise. The EPS was -1.03, surpassing the expected -2.03 by 49.26% . The stock experienced a -1.14% price change on the earnings day and a 12.5% change over the next five days, reflecting market reactions to the results.
How did FBIO’s stock price react after the FY2024Q1 earnings release?
What are the revenue and EPS estimates for FBIO for 2025/Q2?
How does FBIO’s stock price correlate with earnings forecast revisions?
What should investors expect from FBIO’s next earnings report?